Polymorphisms in endothelial nitric oxide synthase and atherogenesis

Slides:



Advertisements
Similar presentations
Part V Second Messengers. The first messengers being the extracellular signal molecules and the third messengers being the large protein kinases and phosphatases.
Advertisements

BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
Today’s lecture More about G proteins Second messengers from lipids Calcium is a second messenger Nitric oxide is a second messenger more neat things about.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Myocardial Microvascular Inflammatory Endothelial.
Atrial Natriuretic Peptides [ANP]
Volume 27, Issue 1, Pages 1-10 (January 2006)
From: Nitric Oxide: A Physiologic Messenger
The DDAH/ADMA/NOS pathway
Sustaining Proliferative Signaling and Evading Growth Suppressors
Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.
Volume 4, Issue 3, Pages (June 2006)
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors  Tobias S. Köhler,
HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model  Eric S. Weiss, MD,
Volume 151, Issue 2, Pages (February 2017)
Accelerating drug discovery: Open source cancer cell biology?
Prasad V. Gade, MD, José A. Andrades, PhD, Marcel E
David G. Cable, MD, James A. Caccitolo, MD, Eric A
Physiology of the endothelium
Figure 3 Mechanisms by which oestradiol reduces
Cell to Cell Communication via Steroids & Hormones
Alcohol and toxicity Journal of Hepatology
Volume 114, Issue 4, Pages (April 1998)
Gene Therapy for Erectile Dysfunction: Fact or Fiction?
Vascular endothelial dysfunction in cirrhosis
Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 
Stephen M Prescott, Raymond L White  Cell 
Volume 64, Issue 1, Pages (July 2003)
Atrial Natriuretic Peptides [ANP]
Volume 151, Issue 2, Pages (February 2017)
Postmortem and ex vivo carbon monoxide ventilation reduces injury in rat lungs transplanted from non–heart-beating donors  Boming Dong, MD, PhD, Paul.
Divya Gupta et al. JCHF 2013;1:
Volume 66, Issue 6, Pages (December 2004)
Evaluation of the microcirculation in vascular disease
In vivo genetics of anaesthetic action
Volume 68, Issue 2, Pages (October 2010)
Hao G. Nguyen, MD, PhD, Amit Korach, MD, Chey Collura, MA, Benjamin R
Opioids and neovascularization; pro or anti?
Pharmacology of coronary artery bypass grafts
Yasuko Iwakiri, Vijay Shah, Don C. Rockey  Journal of Hepatology 
Mark S Taylor, A.Marie McMahon, Jason D Gardner, Joseph N Benoit 
The sources of oxidative stress in the vessel wall
Annette Ebner, PhD, David M. Poitz, PhD, Antje Augstein, PhD, Ruth H
Photoreceptors: Unconventional Ways of Seeing
Guo-Wei He, MD, DSc, David P. Taggart, FRCS 
Thomas Quaschning, Jan Galle, Christoph Wanner
Juan-Carlos García-Pagán, Jorge Gracia-Sancho, Jaume Bosch 
Margus Annuk, Mihkel Zilmer, Bengt Fellström
Protein kinase Cα: disease regulator and therapeutic target
Volume 86, Issue 2, Pages (August 2014)
Nitric Oxide Synthase and Adenylyl and Guanylyl Cyclase Activity in Porcine Interposition Vein Grafts  Jamie Y Jeremy, PhD, Michael R Dashwood, PhD, Maureen.
Mary P. Kotlarczyk, PhD, Marie Billaud, PhD, Benjamin R
Nitric oxide in acute renal failure: NOS versus NOS
FOXO transcription factors
Endothelial Nitric Oxide Synthase in Bicuspid Aortic Valve Disease
Thomas Mueller, Benjamin Dieplinger  Kidney International 
Anthony M. Dewar, Richard A. Clark, Adam J. Singer, Mary D. Frame 
Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease  Shen Xiao, Laszlo Wagner, Rebecca J. Schmidt,
Osteoarthritis year in review 2016: genetics, genomics and epigenetics
Evaluation and Medical Management of Erectile Dysfunction
Histochemical assessment of nitric oxide synthase activity in aortic endothelial cells of streptozotocin-induced diabetic rats  M Shafiei, M Nobakht,
Role of Nitric Oxide Pathway in Placental Dysfunction Following Fetal Bypass  Christopher Lam, BS, R. Scott Baker, BS, Jerri McNamara, CCP, Robert Ferguson,
Constantijn Franssen et al. JCHF 2016;4:
Alterations in expression of endometrial endothelial nitric oxide synthase and αvβ3 integrin in women with endometriosis  Omid Khorram, M.D., Ph.D., Bruce.
Cigarette smoke inhibits endometrial epithelial cell proliferation through a nitric oxide– mediated pathway  Omid Khorram, M.D., Ph.D., Guang Han, M.D.,
Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies  Ben M Tsai, MD, Meijing Wang, MD, Mark W Turrentine,
Mechanism of action for pulmonary arterial hypertension medications.
Biology of endothelin receptors in the collecting duct
Evaluation and Medical Management of Erectile Dysfunction
Jurgen Schnermann, Josephine P. Briggs  Kidney International 
Presentation transcript:

Polymorphisms in endothelial nitric oxide synthase and atherogenesis Aroon D Hingorani  Atherosclerosis  Volume 154, Issue 3, Pages 521-527 (February 2001) DOI: 10.1016/S0021-9150(00)00699-7

Fig. 1 Model summarising the mechanism by which common polymorphisms influence the susceptibility to complex disorder such as atherosclerosis. In single gene disorders (left panel) rare mutations in genes result in a major disturbance in the function of the encoded protein that is both necessary and sufficient to result in disease. In contrast in complex disorders (right panel), common polymorphisms cause a subtle alteration in the expression or activity of the encoded protein that is compatible with health but which, in the presence of additional adverse environmental or genetic influences leads to the development of the disease. Atherosclerosis 2001 154, 521-527DOI: (10.1016/S0021-9150(00)00699-7)

Fig. 2 Nitric oxide is synthesised from l-arginine by eNOS. NO is not stored and therefore regulation of its availability is through changes in the expression or activity of eNOS or through changes in the concentration of endogenous inhibitors or activators. Atherosclerosis 2001 154, 521-527DOI: (10.1016/S0021-9150(00)00699-7)

Fig. 3 Actions of endothelium-derived NO. NO is highly diffusible and influences the biology of a wide variety of cell types (see text). Most of the actions of NO on target cells are mediated through an elevation in cGMP. GTP, guanosine triphosphate; GC, souble guanylate cyclase; cGMP, cyclic guanosine monophosphate. Atherosclerosis 2001 154, 521-527DOI: (10.1016/S0021-9150(00)00699-7)

Fig. 4 Comprehensive polymorphism map of human eNOS. (A) Gene organisation (B) Detail of the promotor. Atherosclerosis 2001 154, 521-527DOI: (10.1016/S0021-9150(00)00699-7)

Fig. 5 Enzymatic studies of recombinant eNOS Glu298 and Asp 298. No discernable differences were detected between these two forms of eNOS with respect to substrate or co-factor/activity relationships or the effects of inhibitors. Atherosclerosis 2001 154, 521-527DOI: (10.1016/S0021-9150(00)00699-7)